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Short-term supplementation of celecoxib-shifted butyrate
production on a simulated model of the gut microbial
ecosystem and ameliorated in vitro inflammation
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Tom Van de Wiele1✉
Celecoxib has been effective in the prevention and treatment of chronic inflammatory disorders through inhibition of altered
cyclooxygenase-2 (COX-2) pathways. Despite the benefits, continuous administration may increase risk of cardiovascular events.
Understanding microbiome-drug-host interactions is fundamental for improving drug disposition and safety responses of colon-
targeted formulations, but little information is available on the bidirectional interaction between individual microbiomes and
celecoxib. Here, we conducted in vitro batch incubations of human faecal microbiota to obtain a mechanistic proof-of-concept of
the short-term impact of celecoxib on activity and composition of colon bacterial communities. Celecoxib-exposed microbiota
shifted metabolic activity and community composition, whereas total transcriptionally active bacterial population was not
significantly changed. Butyrate production decreased by 50% in a donor-dependent manner, suggesting that celecoxib impacts
in vitro fermentation. Microbiota-derived acetate has been associated with inhibition of cancer markers and our results suggest
uptake of acetate for bacterial functions when celecoxib was supplied, which potentially favoured bacterial competition for acetyl-
CoA. We further assessed whether colon microbiota modulates anti-inflammatory efficacy of celecoxib using a simplified
inflammation model, and a novel in vitro simulation of the enterohepatic metabolism. Celecoxib was responsible for only 5% of the
variance in bacterial community composition but celecoxib-exposed microbiota preserved barrier function and decreased
concentrations of IL-8 and CXCL16 in a donor-dependent manner in our two models simulating gut inflammatory milieu. Our
results suggest that celecoxib-microbiome-host interactions may not only elicit adaptations in community composition but also in
microbiota functionality, and these may need to be considered for guaranteeing efficient COX-2 inhibition.
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INTRODUCTION
Prostaglandin E2 (PGE2) is a key mucosal inflammatory mediator
produced when membrane phospholipids are metabolized by
cyclooxygenase (COX) enzymes. Increased synthesis of prosta-
glandins is a feature of chronic inflammation1 and has been
proposed to promote tumorigenesis in the colon.2 Previous
research showed that COX-2 expression correlates to invasiveness,
prognosis, and survival in some cancers,3 such as colorectal cancer
(CRC),4 causing proliferation, enhanced angiogenesis and apop-
tosis suppression.5 In this way, COX-2 inhibitors such as celecoxib
(CX) are promising chemopreventive agents for chronic pain,
inflammatory and mood disorders6 and CRC.7 Additionally, CX has
demonstrated anti-inflammatory and analgesic effects, with lower
incidence of upper gastrointestinal ulceration and complications
during single and multiple administration for inflammatory
conditions.8 Despite these benefits, their long-term use may shift
cardiovascular homeostasis, inhibiting biosynthesis of vascular
COX-2-dependent prostacyclin (PGI2)
9 increasing risk for cardio-
vascular events,10 renal ischaemia,11 impaired fracture healing and
peripheral oedema.12
Advances in omics techniques have provided insights on the
role of the gut microbiome in cancer development.13 Currently,
the driver-passenger model suggests that intestinal “driver”
bacteria contribute to initiate CRC by damaging epithelial
DNA.14 This microenvironment alteration impairs barrier function
and favours opportunistic “passenger” bacteria, placing selective
pressure on the microbiome.14
When colon-targeted drugs are orally administered, they
encounter the gut microbiota before reaching host tissues.
Microbial drug metabolism may impact drug stability and activity,
influencing toxicity and inflammation on the host.15 Conversely,
drugs may also alter the gut microbiota, modulating community
structure, and potentially resulting in dysbiosis.16 Understanding
microbiome-drug-host interactions is crucial to assess the
potential impact on ADME and safety responses of intestinal
targets. Although the gut microbiome plays an enormous role in
patient health, and in pharmacokinetic and pharmacodynamic
response,17 pharmaceutical companies only recently started to
explore the microbiome as potential contributor to drug out-
comes. Similarly, regulatory agencies are not currently considering
gut bacteria within the official evaluations before approval of
colon-targeted drugs. Besides the microbial modulation of drug
bioavailability and pharmacokinetics,15 low solubility and small
aqueous volumes in the colon may hinder drug efficacy.18 As
interest in developing novel colon-targeted NSAID delivery
systems has increased, insight into the presystemic biotransforma-
tion by the gut microbiota is fundamental. In vitro studies showed
that bacteria can metabolize CX,19 potentially jeopardizing its anti-
inflammatory effects. Additionally, whether CX presence can
modulate the host-microbiome crosstalk remains unresolved.
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Prior reports correlating gut microbiome changes with CX
treatment relied on DNA amplicon sequencing.20 As the presence
of dead bacterial cells may obscure the interpretation of
microbiome data, we analysed the bacterial community composi-
tion based on cDNA, as a proxy for the metabolically active
community.
CX can be absorbed throughout the GI tract, but 85% of the
dose is eliminated through urine and faeces.8 Overall systemic
absorption of poorly soluble drugs may be improved with colon-
delivery systems,21 because colonic transit times (17–24 h)21,22 are
longer compared to those of the small intestine (3–4 h). Thus, we
simulated delivery of a clinical dose of CX8,23,24 in a proximal
colon-targeted formulation. We aimed at screening short-term
bidirectional interactions between CX and diversity, composition
and functionality of the human microbiome using an in vitro
model of the proximal colon, and at further elucidating the
ultimate impact of the microbiota on the anti-inflammatory
efficacy of CX.
RESULTS
CX impacts bacterial fermentative metabolism in a donor-
dependent manner
CX-microbiota interactions were evaluated under proximal colon
conditions (pH 5.6–5.9, 37 °C, 16 h of transit time25–27), as
absorption of poorly soluble drugs may be improved using
colon-delivery systems.21 Short-chain fatty acids (SCFAs) were
used to monitor functional activities of the colon communities
following exposure to CX or its vehicle (PEG). Measurements in
volunteers 1 and 2 were missed at the time 0 h (Table 1). Total
SCFA production from separate faecal microbiota incubations of
eight different individuals was significantly lower for CX incuba-
tions compared to those with PEG (P < 0.05, Table 1b), but pH
remained stable throughout the experiment (Supplementary
Table 1). While the 60:20:20 ratio of the three major SCFA (acetate,
propionate, and butyrate) was consistent across donors at the
initial time point (60:16:7, Table 1a), a shift was evident at the end
of the incubation (line 15, Supplementary Table 1). Only the mean
relative proportion of acetate tended to be higher with CX
(P= 0.06, Supplementary Table 1), while both relative and
absolute concentrations of butyrate and propionate per individual
were higher with PEG compared to those with CX (Table 1b). In
fact, CX significantly lowered mean butyrate after 16 h (P < 0.05,
Supplementary Table 1), except in donors 1, 4 and 8 (Table 1b).
Total active bacterial load remained unchanged when CX was
supplemented (Supplementary Table 2), but large variation was
observed (Supplementary Table 1). These findings might indicate
that bacteria either alter their metabolic activity when exposed to
CX or that changes in bacterial composition lead to shifts in
fermentation profiles.
Bacterial abundance remains stable, but individual microbiome
diversity and composition shifted following CX supplementation
Total DNA may also include that of dead bacterial cells, so we
analysed community composition based on cDNA, as a proxy for
the metabolically active bacterial community. Quantitative RT-PCR
revealed that total 16S rRNA gene copy numbers from metabo-
lically active bacteria were not significantly different between
treatments, across donors (Supplementary Table 2). In contrast,
community composition and structure tended to be influenced, as
CX was associated with reduced but not significantly different
Inverse Simpson alpha diversity index at the end of the incubation
(Fig. 1, Table 2a, b). Permutational multivariate analysis of variance
(PERMANOVA) confirmed that donor, but not treatment, signifi-
cantly contributed to the differences in the mean relative
abundances of bacterial genera (P < 0.001, Fig. 2, Table 2b). We
observed that CX decreased alpha diversity when assessed
individually (Supplementary Table 3, Fig. 3). Although interindivi-
dual variability was significant, the metabolically active taxa with
the highest relative abundances proportional to the entire
microbiome of control incubations were: Bacteroides sp., Faecali-
bacterium sp., Ruminococcaceae UGC002, and Megasphaera sp. In
contrast, Alistipes sp., Dialister sp., Escherichia-Shigella sp., Lachnos-
pira sp., Megamonas sp., Parabacteroides sp., Roseburia sp., and
Sutterella sp. were highly abundant when CX was supplied (Fig. 3).
Additionally, Anaerostipes sp., Coprococcus 2, Erysipelotrichaceae
UCG 003, Flavonifractor sp., Parabacteroides sp., Paraprevotella sp.,
Parasutterella sp., Phascolarctobacterium sp., Ruminoclostridium
Table 1. Relative percentages of the three major short-chain fatty acids (SCFA) derived from microbial fermentation, following supplementation with
either celecoxib (CX) or the carrier (PEG) at the (A) beginning of the incubation (0 h, n= 6).
SCFA (%) Ratio found in colon and stool83 Donor 3 Donor 4 Donor 5 Donor 6 Donor 7 Donor 8
CX PEG CX PEG CX PEG CX PEG CX PEG CX PEG
(A)
Acetate 60 60.02 65.71 35.45 39.30 63.90 65.32 59.25 63.42 40.88 41.84 49.98 53.97
Propionate 20 23.20 21.64 14.84 14.46 12.63 12.48 12.83 11.70 14.20 13.97 10.61 10.81






Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 Donor 7 Donor 8
CX PEG CX PEG CX PEG CX PEG CX PEG CX PEG CX PEG CX PEG
(B)
Acetate 60 49.41 47.15 74.64 62.51** 22.46 28.97 33.32 34.76 73.82 57.87*** 84.89 63.64*** 68.12 67.87 73.99 69.94
Propionate 20 17.30 18.05 22.40 18.27 21.01 18.89 6.90 9.06 14.96 16.13 12.58 18.93** 16.14 13.88 14.18 13.48
Butyrate 20 15.13 17.15 2.27 17.89*** 4.83 11.76*** 7.51 7.89 6.04 19.48*** 2.46 13.01*** 8.15 10.29** 7.66 8.07
Means between treatments were not significantly different and samples from donors 1 and 2 were missed at this time point. Quantification of relative SCFA
percentage was completed again when incubation was finalized after 16 h (B). N= 8; **P < 0.05; ***P < 0.0001.
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5 sp., Ruminiclostridium 6 sp., Ruminococcaceae UCG 010,
Ruminococcus 2 sp., Veillonella sp., and Victivallis sp., were
significantly different as a result of the donor*treatment*time
point interaction (Supplementary 4). From all the community
metrics, mean richness was the only one showing a trend for
decrease when CX was supplied (P= 0.07, Table 2b) but our
findings suggest that the individual microbiome is highly variable
and is resistant to external stressors.
Short-term exposure to CX increases number of community
metabolic networks
Association networks were constructed to highlight potential
shifts among bacterial relative abundances after short-term
exposure to CX or its vehicle. The number of links in the network
was lower when the vehicle PEG alone was provided (Fig. 4a). The
central position of Phascolarctobacterium, Parabacteroides, Copro-
coccus 2 and Unclassified Victivallales and the linkages among
these genera suggest concomitant changes in their relative
abundances in the presence of PEG. The central position of the
acetate-producing Erysipelatoclostridium in the CX network
(Fig. 4b) indicated that its relative abundance was associated
with Subdoligranulum, a butyrate and lactate-producing genus, in
a donor-dependent manner (P < 0.05, Supplementary Table 4).
Networks connecting bacterial load, metabolites and relative
abundances were assembled to monitor functional alterations
associated with changes in genera abundances. Activity-based
relative abundance of Bacteroides was positively associated with
butyrate, propionate and valerate levels and total 16S rRNA gene
copy number in presence of PEG (Fig. 5a, Supplementary Table 4).
These results confirmed that Bacteroides was one of the most
abundant active genera, as first suggested in Fig. 3. Higher number
of links in comparison with PEG were detected after 16 h of
exposure to CX (Fig. 5). Indeed, one network linking acetate with the
relative abundance of diverse taxa was only present when CX was
supplied and contained the largest number of active genera
participating. Relative abundance of Faecalibacterium decreased
over time with CX supplementation, corresponding with the decline
in butyrate levels (Fig. 3). However, this genus tended to be
positively associated with acetate production (Fig. 5b). Relative
abundance of active Lachnoclostridium was significantly associated
with butyrate in the CX treatment (Fig. 5b). Here, Oscillospira,
Allisonella, Hungatella and Streptococcus were linked because they
possibly participated in butyrate production as well. Megamonas
and Megasphaera were other genera with high relative abundances
positively associated with branched-chain SCFA and isovalerate. The
associations between the latter metabolites and Colinsella remained
unchanged upon CX exposure, suggesting that this community
function is either independent from drug supplementation or
directly associated with PEG addition (Fig. 5a, b). Similarly,
associations between Allisonella (butyrate consumer), Streptococcus
(butyrate producer) and butyrate were common for both treat-
ments. Results from the network analysis indicate that shifts in the
community metabolic activity upon short-term supplementation of
CX potentially impacted butyrate production.
Inter-individual differences play a role in reduction of in vitro
inflammation when CX is presented to the microbiome
Understanding the microbial interactions with the host epithelium
is essential to assess whether the anti-inflammatory efficacy of CX
remains unaltered following exposure to the simulated micro-
biome. The THP-1 cell line (macrophage-like) is known to be a
suitable, simplified, and reliable model to study macrophage
functions28 and inflammatory responses to external stimuli in the
surrounding environment, such as drugs.29,30 We initially per-
formed a mechanistic study to examine the inflammatory
response mediated by CX using these cells. We further verified
the microbiome impact using a multicellular model simulating the
enterohepatic ecosystem, including enterocyte-like and goblet-
like cell lines, plus THP-1 cells. This set-up enabled closer
communication between cell lines,31 as would occur when
macrophages infiltrate the underlying intestinal mucosa.32
We considered IL-8 and TEER appropriate indicative markers of
intestinal inflammation, because they have been described as
hallmark for inflammatory response and epithelial barrier function,
Fig. 1 Inverse Simpson index (D2) was used to assess alpha diversity at the start (0 h) and at the end of the incubation (16 h post
treatment) on each volunteer. Horizontal bars indicate means and distribution of each data point. Alpha diversity is indicated in green boxes
for celecoxib treatment (CX), and in purple when the control treatment with the vehicle (PEG) was supplied. *P < 0.05.
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both in vitro and in vivo.33 In addition to IL-8, another cytokine
involved in intestinal inflammation (CXCL-16)34 was quantified.
Direct contact of macrophage-like cells with filter-sterilized
supernatants from the CX-exposed microbiota resulted in a
variable outcome in IL-8 and CXCL-16 concentrations. Compared
with the PEG controls, a decrease in IL-8 and CXCL-16 was only
observed in four out of eight individuals (Fig. 6a, b). Only two
volunteers (D2 and D6) showed concomitant decrease of IL-8 and
CXCL-16, while one person showed increased concentrations of
both chemokines following supplementation with CX (D8)
(Supplementary Table 5). These results suggest that successfully
decreased inflammation potentially occurred with lowered
recruitment and infiltration of leukocytes in the epithelial cells.
High IL-8 concentrations were found when non-bacterially
exposed CX was applied in the enterohepatic model (Fig. 6c). In
contrast, the lowest concentration of IL-8 and thus the most
significant decrease in inflammatory response was found with the
CX-exposed supernatant of donor 6 (P < 0.05, Table 3), which
showed decreased butyrate concentrations and was considered
“responder” to CX. CX that was not in contact with bacteria
promoted the highest decrease in transepithelial electrical
resistance (TEER) (P < 0.05, Table 3), in comparison with super-
natants from CX-exposed bacteria. This outcome indicates less
damage to epithelial barrier function and decreased inflammatory
response when gut microbiota was exposed to CX.
DISCUSSION
The lipophilic characteristics of CX favour metabolic elimination,35
and exploring only the pathways for CX distribution in the host is
insufficient for assessing drug bioavailability. In vitro models have
been applied to simulate drug-bug associations in the human
gut,36,37 but the impact of NSAIDs on the metabolic activities of
the microbiome has been overlooked. Previous studies reported
the influence of NSAIDs on the gut microbiome,38 yet no changes
in bacterial richness, microbiome composition or beta diversity
were found when CX was supplied.20 These results screened
community structure using DNA-based amplicon sequencing,
which may also include DNA of dead bacterial cells. As such
approach may deliver a partial overview, we used cDNA as an
indicator of the metabolically active bacterial population and we
performed community composition analyses based on informa-
tion from transcribed RNA.39 In this way, we intended to highlight
the main bacterial genera in the RNA pool whose metabolic
activities were impacted by CX. We confirmed that mean activity-
based cell load, composition, diversity and richness were not
significantly different among donors, and the only alterations
were on the bacterial metabolic activities. PERMANOVA analysis
suggested that donor was the main driver of the interindividual
dissimilarities in the most abundant genera between treatments.
The similar total active bacterial load observed between
treatments may indicate that CX mainly inhibited functional
activities of groups of bacteria rather than those of single genera,
ultimately impacting community fermentation.40 CX users have
been reported to have enrichment of Enterobacteriaceae and
Acidaminococcaceae.38 Here, we validated that the relative
abundance of transcriptionally active Escherichia-Shigella (Enter-
obacteriaceae) was increased with CX supplementation, whereas
the relative abundance of active Acidaminococcus (Acidaminococ-
caceae) was positively associated with acetate in the same
treatment. Coriobacteriaceae (Colinsella) has been proposed to
participate in xenobiotic metabolism by decreasing levels of serine
and glycine,40 which can be both fermented to acetate in the
gut.41 We observed that the relative abundance of this genus was
positively associated with isovalerate levels when CX was added.
As indicated on its corresponding KEGG module, Colinsella
aerofaciens has the capacity of using isovalerate for synthesizing
leucin and serine,42 confirming its potential xenobiotic role in our
study. These results highlight the applicability of our in vitro
model for examining drug-microbiome interactions. The capacity
of Alistipes for producing succinate43 may explain its association
with propionate in the PEG treatment. Dialister was another
succinate producer44 present at high relative abundance, which
does not seem to participate in the propionate network when PEG
was supplied. This suggest that high relative abundance of
transcriptionally active taxa may be result of increased main-
tenance metabolism of that single taxa and not due to cross-
feeding interactions.
Beyond its tumour inhibitory properties,45 butyrate ameliorates
mucosal inflammation and oxidative status, reinforces the
Table 2. Impact of donor and supplementation of celecoxib (CX) or vehicle (PEG) on bacterial community metrics at (A) the beginning of the
incubation (0 h, n= 6) and (B) once the incubation was finalized (16 h, n= 8).
Metric Index Treatment SEM P value of each effect
CX PEG Treatment Donor Treatment*Donor interaction
(A)
Evenness Pielou 0.61 0.60 0.0009 0.83 0.0001 0.23
Alpha diversity Shannon (H’) 2.71 2.72 0.03 0.81 <0.0001 0.13
Simpson 0.85 0.85 0.007 0.43 <0.0001 0.04
Inverse Simpson (D2) 8.00 8.48 0.53 0.54 <0.0001 0.76
Fisher’s diversity 13.41 13.16 0.25 0.49 <0.0001 0.34
Richness Total richness (S) 92.50 95.83 3.83 0.55 0.002 0.77
Abundance Chao 144.12 128.55 9.54 0.27 0.01 0.59
(B)
Evenness Pielou 0.55 0.59 0.01 0.06 0.003 0.38
Alpha diversity Shannon (H’) 2.54 2.70 0.06 0.08 0.001 0.33
Simpson 0.84 0.86 0.009 0.14 0.009 0.10
Inverse Simpson (D2) 7.59 8.13 0.63 0.55 0.02 0.23
Fisher’s diversity 13.28 13.17 0.25 0.49 <0.0001 0.34
Richness Total richness (S) 92.56 97.12 2.78 0.88 0.005 0.07
Abundance Chao 94.01 114.65 5.34 0.01 0.008 0.89
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epithelial defence barrier, and modulates visceral sensitivity and
intestinal motility.46 Thus, the inflammation-butyrate interplay is
not only a direct effect of altered SCFAs concentrations, but also
associated with changes in microbiome functionality. The
significantly lower butyrate concentration post-CX delivery may
have several implications. Indeed, the protecting properties of CX
towards CRC47,48 may be partially derived from lowering bacteria-
derived butyrate. Nutrients can be utilized in their final form by
both host and gut microbes, leading to competition for
resources.49 In fact, blocking fatty acid supply and host recapture
has been proposed as strategy for influencing cancer cell
bioenergetics,50,51 but few studies have addressed the potential
role of acetate in cancer.52 Acetyl-CoA is the main carbon source in
mammalian cells, and the ligation of acetate and CoA by acetyl-
CoA synthetase (ACSS) contributes to the supply of this
metabolite.52 Cancer cells use acetyl Co-A during aerobic
metabolism regardless of stress conditions.52 Butyrate is also
metabolized to acetyl-CoA,45 inhibiting tumour growth via
silencing acetyl-CoA synthetases50 or potentially through acetate
uptake. As acetyl-CoA is a bacterial substrate for fatty acid
production,53 our network analysis suggests that acetate was used
for bacterial metabolic functions when CX was supplied. Thus, CX
may favour bacterial competition for acetyl Co-A, generating
potential host protective effects. Indeed, microbiota-derived
acetate has been associated with inhibition of cancer-associated
deacetylation.54 Increasing acetate concentration shifts SCFA
ratios,55 decreasing butyrate and explaining why the acetate:
propionate:butyrate ratios tended to change when CX was
supplied. Faecalibacterium sp. is a well-known butyrate producer
and acetate consumer55 and its presence in the acetate network
may indicate that the relative abundance of this genus increased
when CX was provided and acetate levels increased.
Synthesis of reduced products including H2, succinate, and
butyrate creates redox balance during colonic fermentation,
whereas formation of oxidized products, such as acetate, is
associated with bacterial ATP production.53 Fermentative activities
of Lachnoclostridium yield ethanol, acetate, CO2 and H2,
56,57
explaining the numerous links with other genera in the CX
network. These potential cross-feeding interactions,58,59 may
support its positive association with the total 16S rRNA gene
copy number. Acetate is a co-substrate for butyrate production,60
but butyrate production may be reduced when NADH is used for
H2 formation during glycolysis. Thus, NADH is not available to
convert acetoacetyl-CoA to butyryl-CoA and butyrate concentra-
tions decrease.53 Acetate-producing Lachnoclostridium and Oscil-
lospira possess transporters involved in uptake of oligosaccharides
and glycerol-P,58 explaining their potential involvement in the
shift from butyrate to acetate production when CX was supplied.
Additionally, Peptococcaceae uses the acetyl-CoA pathway in a
reverse direction to oxidize butyrate.61 Acetyl Co-A is conse-
quently routed into acetate formation,60 which is energetically
advantageous for bacterial use.53 In fact, butyrate producers may
shift metabolic pathways towards acetate under stress condi-
tions.62 Previous research showed that other acetate producers
such as Bacteroidetes and Prevotellaceae positively correlated to
butyrate-producing communities using the acetyl CoA pathway
for butyrate production,61 supporting the potential shift in
butyrate towards acetate observed in our study.63
Although the role of SCFA on chronic inflammatory diseases has
been documented, most of the studies lack natural commensal
microbiota cross-talking with host cells.45,64 Interindividual differ-
ences in microbiome significantly impact drug responses,16 and
thus it is paramount elucidating whether their microbiome
fermentation products and NSAIDs work together for resolving
inflammation. CX was responsible for only 5% of the variance in
bacterial community composition among the eight donors, but
the effect of CX-exposed bacteria on the proinflammatory IL-8 was
sufficient to be detected in a donor-dependent manner. Moreover,
samples derived from 50% of the donors showed increased CXCL-
16, which effectively reduces pro-inflammatory macrophages in
the liver65 and is a marker of favourable prognosis in CRC.66
Butyrate specifically suppresses proinflammatory effectors in
lamina propria macrophages.67 The results observed in the cell
model suggest that the interaction between CX and microbiome
to resolve inflammation may be not exclusively related to
community composition or bacterial abundance, and microbiome
functionality must be considered. Thus, when either the abun-
dance or activity of butyrate producers is lowered in chronic
inflammation,68,69 CX may compensate for the anti-inflammatory
effect of butyrate and support the resolution of the inflammatory
process. While butyrate seemed to be reduced with short-term
treatment, Acetate:Propionate:Butyrate ratio and relative levels of
acetate (of the total SCFA) may be other bacterial metabolism
variables relevant for assessing successful reduction on inflamma-
tion following NSAIDs administration. Hence, using multicompart-
ment cell models for future studies assessing the crosstalk of the
microbiota and colon primary cells or organoids, in the context of
chronic inflammatory diseases, are imperative.
As indicated in our study, gut microbiome activities and its
interplay with the host can be modulated through CX. Certainly,
individual microbiome may need to be considered before
supplementing CX as a colon-targeted drug in the context of
chronic inflammation and CRC. Divergence in the molecular
Fig. 2 Interindividual differences drive bacterial community
composition. Principal coordinate analysis (PCoA) revealed that a
donor significantly contributed to variations among individual
microbiomes, but not time b. The variance explained by experi-
mental factors (P < 0.01) was calculated using PERMANOVA (top
right) and confirmed differences in community structure between
volunteers. n= 6 at 0 h, n= 8 at 16 h.
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approaches (i.e. next generation sequencing, qPCR) used for
investigating inflammation-associated microbiome signatures
contributes to the lack of consensus on the composition of
microbiota in patients with chronic inflammatory diseases. Our
in vitro model retained interindividual variability, allowing for
mechanistic research on drug-microbiota-host interplay, funda-
mental for developing individualized therapeutic strategies.
Focusing on functionality rather than taxonomic diversity may
be the next frontier for developing predictive markers of
inflammation-induced dysbiosis and NSAID efficacy.
METHODS
Faecal incubations simulating the proximal colon environment
Batch incubations of faecal samples were conducted using phosphate-
buffered nutritional medium (pH 5.9, 0.1 M) containing (per litre): 12.25 g of
KH2PO4 (Carl Roth GmbH, Karlsruhe, Germany), 1.78 g of Na2HPO4 (Carl
Roth GmbH, Karlsruhe, Germany), 3 g of yeast extract (Oxoid Ltd,
Basingstoke, Hampshire, England), 1 g of proteose peptone (Oxoid Ltd,
Basingstoke, Hampshire, England), 0.25 g of gum Arabic from acacia tree
(Sigma Aldrich Co., St-Louis, USA), 0.5 g of apple pectin (Sigma Aldrich Co.,
St-Louis, USA), 0.25 g of xylan (Carl Roth GmbH, Karlsruhe, Germany), 1 g of
potato starch (Prodigest, Zwijnaarde, Belgium), and 4 g of mucin from
porcine stomach Type II (Sigma Aldrich Co., St-Louis, USA).
Faecal material was obtained from eight healthy, non-obese, non-
smoking volunteers (4M and 4F, 30 ± 2.8 yo), following an omnivorous diet
and without antibiotic exposure for the prior 6 months. Stool samples were
collected in a closed recipient under microaerophilic conditions (Anaero-
Gen, Oxoid, Hampshire, UK) and homogenized 1:5 (w/v) in anaerobic
potassium phosphate buffer (0.1 M at pH 7.0) containing 1 g/L of sodium
thioglycolate as reducing agent, and centrifuged during 2min at 500 × g to
obtain faecal slurries of 20% (w/v). CX (Janssen Pharmaceutica, Beerse,
Belgium) was dissolved in 70:30 (v/v) PEG400:H2O as vehicle, at a stock
concentration of 100mg/mL. The administered dose was established
based on data from the manufacturer and intended for a colon-targeted
formulation. For each donor, triplicate incubations of 10% faecal slurry,
100mg/mL of CX or 70:30 (v/v) PEG400 (Acros, Geel, Belgium):H2O, and
nutritional medium (final volume= 175mL) were performed for 16 h at
37 °C in a shaking incubator at 120 rpm (New Brunswick Scientific InnOva
4080 Incubator Shaker, Wezembeek-Oppem, Belgium), under anaerobic
conditions (90%–10% N2/CO2). Once the incubation was completed,
samples were collected, flash-frozen using liquid nitrogen and preserved at
−80 °C for further analysis. Samples from volunteers 1 and 2 were missed
at the 0 h collection point.
Surveying community functionality and composition
SCFAs production. SCFA were used as benchmarks of community activity.
Extraction from samples was performed with diethyl ether, after the
addition of 2-methyl hexanoic acid as an internal standard. Extracts were
analysed using a GC-2014 gas chromatograph (Shimadzu, ‘s-Hertogen-
bosch, the Netherlands), equipped with a capillary fatty acid-free EC-1000
Econo-Cap column (dimensions: 25–0.53mm, film thickness 1.2 mM;
Alltech, Laarne, Belgium), a flame ionization detector and a split injector.
The injection volume was 1 mL and the temperature profile was set from
110 to 160 °C, with a temperature increase of 6 °C/min. The carrier gas was
nitrogen and the temperature of the injector and detector were 100 and
220 °C, respectively. Differences in SCFA concentrations among treatments
were compared using a repeated measures mixed model,70 with the
lsmeans adjustment and Bonferroni correction for multiple comparisons
(SAS, 2012). Statistical significance was assumed at P < 0.05.
Quantification of total metabolically active bacterial community. Samples
collected from the faecal incubations at 0 h (start) and after 16 h (end of
experiment) were thawed on ice, centrifuged for 5min at 4 °C and 5000 × g,
and disrupted two times for 25 s at 1400 rpm using a homogenizer
instrument (Power Lyser 24, MO BIO Laboratories, Carlsbad, USA), with a 5-s
interval, where the samples were placed on ice. RNA was further extracted
using the Nucleospin RNA plus kit (Macherey Nagel, Düren, Germany),
following the manufacturer’s instructions. Reverse transcription was
completed using the Reverse Transcriptase Core kit (Eurogentec, Seraing,
Belgium).
For the quantification of total bacterial 16S rRNA gene copy numbers, a
standard curve was constructed using serial dilutions of plasmid DNA from
a clone identified as Bifidobacterium breve LMG 33264. Briefly, universal
bacterial primers 27F and 1492R were used to amplify the full-length 16S
rRNA gene from the plasmid DNA of a Bifidobacterium breve clone. The
resultant PCR product was purified using the InnuPREP PCRpure Kit (AJ
Fig. 3 Relative abundances of bacterial genera occurring on each volunteer when celecoxib (CX) or a control treatment (PEG) were
supplied. Bar plots include the metabolically active taxa with the highest relative abundances proportional to the entire microbiome, at the
beginning (0 h, upper panel) and at the end of the experiment (16 h, lower panel). Data from volunteers 1 and 2 was not collected at the start
of the experiment. Metabolic products of the taxa in the plots are included in the lower panel of the right.
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innuscreen, Berlin, Germany), cloned in E. coli with the TA Cloning Kit (Life
Technologies, Carlsbad, VS) and plasmid extracted with the PureYield
Plasmid Miniprep System (Promega, Leiden, The Netherlands). The mass
concentration of the plasmid was measured using an ND-1000 spectro-
photometer (NanoDrop Technologies, Wilmington, DE), converted to the
molecule concentration71 and copy numbers of total bacteria in 50 ng of
cDNA and per mL of faecal incubation were determined by relating the
threshold cycle (CT) values to the standard curves based on the following
equation: Y=−3.193 × logX+ 35.003 (Y, CT value; X, copy number of 16S
rRNA gene) (r2= 0.996).71
Quantitative reverse transcription-PCR (qRT-PCR) analysis of the meta-
bolically active community was achieved with the StepOnePlus Real-Time
PCR system (Applied Biosystems, Foster City, CA, USA). Amplification
reactions were in: 10 × Taq buffer with KCl, 25mM of MgCl2, 10mM of dNTP
mix, 10 µM of each forward and reverse primers, 20mg/mL of BSA (Thermo
Scientific, Waltham, USA), 1.25 U of Taq Polymerase, 50 ng of cDNA and
0.1 × SYBR Green I ([Invitrogen, Carlsbad, USA] provided at 10 000×, stock
solutions of 20× were prepared in DMSO). qRT-PCR conditions included
10min at 95 °C, followed by 40 cycles of 15 s at 95 °C and 30 s at 60 °C. The
efficiencies (E) of RT-PCR were calculated from the given slopes in
StepOnePlus software using the following equation: E= [10(−1/slope)− 1] ×
100%. Data generated from reactions with efficiencies between 90% and
110% were used for further analysis.71 Differences in copy numbers among
treatments were compared using a repeated measures mixed model,70 with
Fig. 4 Bacterial network of communities exposed to short-term administration of celecoxib (CX) or its vehicle (control treatment, PEG).
This representation uncovers relationships between clusters of genera across donors. a The faecal microbiota exposed only to PEG displayed a
lower number of links, while the networks among taxa were enriched when CX was provided b. Nodes representing bacterial genera with
similar abundances tended to cluster closely. Node diameter indicates the relative abundance of each genus. Different colours have been
assigned to each node representing a bacterial genus. Neighbourhood selection method (MB) was the graphical model inference procedure
selected. The associations described may be considered ‘core’ functional relationships preserved across donors.
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the lsmeans adjustment and Bonferroni correction for multiple comparisons
(SAS, 2012). Statistical significance was assumed at P < 0.05.
Community composition and dynamics
The V5–V6 hypervariable region of the 16S rRNA gene from the cDNA was
amplified using primers 341F and 785R. High-throughput amplicon
sequencing was performed with the Illumina MiSeq platform according
to the manufacturer’s guidelines at LGC Genomics GmbH (Berlin,
Germany). Library preparation and purification as well as bioinformatic
processing are described in the supplemental material.
Data was imported into R using phyloseq72 and taxon abundances
were rescaled by calculating the taxon proportions and multiplying
them by the minimum sample size (n= 2201) present in the data set.73
Inverse Simpson was the metric used for assessing alpha diversity and
Pielou’s index was used as indicator of community evenness.74
Differences in alpha diversity and evenness measures were compared
among treatments using a repeated measures mixed model in SAS
(version 9.4, SAS Institute, Cary, USA). Beta diversity based on Chao and
Bray-Curtis indices was used to examine dissimilarity and determine the
impact of treatment and time on microbial community structure.75 PCoA
was employed to visualize the differences among samples, using the
vegan package in R.76 Stratified PERMANOVA with 999 permutations was
Fig. 5 Community metabolic activity indicates that networks of bacterial interactions were few when the vehicle alone (PEG) was supplied a
and increased following short-term supplementation of celecoxib b. These bipartite networks are based on the regularized canonical
correlations between relative bacterial abundances and relative concentrations of the main short-chain fatty acids. Interactions have been
filtered for an absolute correlation above 0.5 and are coloured following the key shown. Significant interactions are indicated by shorter lines,
and genera with similar abundances within treatment tended to cluster closely.
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conducted to indicate the significance of each covariate (time or
treatment) on the microbial community.
ANOVA was applied to reveal whether the distribution of the genera was
different between treatments over time.76 Because of the over-dispersion
in the OTU data, a zero-inflated negative binomial distribution count
model was used to assess the effect of donor, time and treatment and the
interactions between donor*time*treatment on each individual genus. The
model was selected based on the Akaike Information Criterion (AIC).
Differences among library size sample were accounted for with the offset
option in proc GLIMMIX in SAS.75
Sparse inverse covariance selection was employed to infer an association
network within treatments, using the package SpiecEasi (v0.1.2)77 in R
(v3.5.1). Neighbourhood selection method (S-E(MB) was used to construct a
network of bacterial genera displaying core networks with either functional
or phylogenetic similarities. The calculated adjacency matrix was examined
with the software Gephi 0.9.2,78 using the Fruchterman-Reingold algorithm
for visualizing significant correlations (R ≥ 0.7). This method computes a
layout in which the length of the connections indicates the absolute value
of the correlation. The nodes representing genera whose relative bacterial
abundances have several significant correlations among them were placed
closer to each other in the network.79
Bipartite networks highlighted functional associations among bacterial
genera and metabolites,75 using a pair-wise similarity matrix obtained from
a regularized canonical correlation analysis.80 Values of the similarity matrix
were computed as the correlation between relative abundances of
bacterial genera and metabolic variables, projected onto the space
spanned by the first three components retained in the analysis (r ≥ 0.75).
Genera in the plot were close to correlated variables in the treatment
where they were more abundant.75
Assessing the anti-inflammatory potential of bacteria-exposed CX
Simplified inflammation model. The THP-1 cell line (macrophage-like) is
known to be a suitable, simplified, and reliable model to study
macrophage functions.28 The human monocytic leukaemia cell line THP‐
1 (THP-1, ECACC 88081201, Public Health England, UK) was grown in
Roswell Park Memorial Institute (RPMI) 1640 culture medium (Thermo
Fisher Scientific, Waltham, USA) supplemented with 10% heat-inactivated
foetal bovine serum (iFBS) (Greiner Bio-One, Wemmel, Belgium) and 1%
antibiotic-antimycotic solution (10,000 units/mL of penicillin, 10,000 µg/mL
of streptomycin, and 25 µg/mL of Amphotericin B) (Thermo Fisher
Scientific, Waltham, USA), at 37 °C in 10% CO2 in a humidified incubator.
THP‐1 cells were sub‐cultured twice a week and used between passages 20
and 30.
Macrophage-like phenotype was obtained by treating cells with 25 ng/
mL phorbol 12‐myristate 13‐acetate (PMA, Sigma Aldrich, St-Louis, USA) for
48 h in 24‐well culture plates (Corning, Sigma Aldrich, St-Louis, USA) at a
density of 1 × 105 cells/cm2. Differentiated, plastic‐adherent cells were
washed twice with culture medium (supplemented RPMI 1640 without
PMA) and incubated for 24 h. The cell morphology was analysed by a Zeiss
Primovert inverted microscope (Oberkochen, Germany). Medium was
removed and replaced by supernatant from the eight incubations, passed
through a sterile 0.2 µm filter and diluted five times with RPMI 1640
without supplementation. CX solution at 100mg/mL dissolved in 70:30 (v/
v) PEG:H2O or 70:30 (v/v) PEG:H2O alone were diluted 1:5 with medium and
added as controls of non-bacteria exposed CX and vehicle. This dilution
step was performed to simulate low solubility and the small aqueous
volume in the colon.18 LPS (100 ng/mL) dissolved in RPMI 1640 was added
to the cells to simulate systemic inflammation, as in CRC. The control used
in all measurements was PMA-differentiated THP‐1 macrophages exposed
to the culture medium.
Development of an in vitro model of the enterohepatic system. A novel
model including intestinal epithelial (Caco-2, ECACC 86010202), goblet
(HT29-MTX-E12 ECACC 12040401, Public Health England, UK), hepatic
(HepG2 ATCC HB-8065, Molsheim, France), and immune-like cells (THP-1,
ECACC 88081201, Public Health England, UK) was developed to study host-
drug-microbiome interactions.31,81 Cell layers were grown in a double-
chamber insert (Corning, Sigma Aldrich, St-Louis, USA), and maintained for
23 days. Briefly, 100 µL of a THP-1 cell suspension (106 cells/mL) in 20mg/
mL collagen from rat tail type I (Sigma Aldrich, St. Louis, USA) were spread
in the basolateral surface of inverted inserts. After 45 min of incubation at
37 °C and 10% CO2, a 9:1 cell suspension of Caco-2/HT29-MTX cells (density
of 7.5 × 104 cells/cm2) was added to the apical side of the insert in 1.5 mL
of Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
(v/v) of iFBS and 1% of antibiotic-antimycotic solution (v/v). The basolateral
compartment of the double-chamber system was filled with 2mL of
supplemented RPMI 1640, and the medium was refreshed every 48 h.
Inserts were transferred to six-well plates with pre-seeded HepG2 cells at
Fig. 6 Concentration of pro-inflammatory cytokines was
decreased in a donor-dependent manner when celecoxib was
supplied. Volunteers are numbered consecutively as D1–D8. a IL-8 was
significantly lower in the simplified inflammation model subjected to
the bacteria-exposed celecoxib of three of the volunteers screened (D1,
D2 and D6). Three additional volunteers (D3, D5 and D7) showed a
trend for decreased IL-8, but it was not significantly lower than the
control treatment. b CXCL16 was significantly lower in the simplified
inflammation model subjected to the bacteria-exposed celecoxib from
only two volunteers (D2 and D6) and tended to be decreased in other
two (D3 and D4). c The two volunteers with the most extreme
metabolic responses in butyrate production were selected to be
screened in a multicompartment cell model resembling the enter-
ohepatic system. Volunteer 6 (D6) had the most significant decrease in
butyrate levels and was considered “responder” to the CX treatment.
Volunteer 8 (D8) did not show any significant difference in butyrate
between the control and the treatment after 16 h of incubation and it
was considered as “non-responder”. IL-8 concentration was significantly
lower in the model subjected to the supernatant of D6 containing
bacteria-exposed celecoxib (“responder volunteer”). The opposite
effect was observed in D8 (“non-responder volunteer”), suggesting
that interindividual differences in the functionality of the microbiome
may play a role in the response to anti-inflammatory drugs. N= 8, “*”
indicates P < 0.05 between volunteers. Error bar indicates SEM.
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day 19 post-seeding, when the cell culture media in the basal
compartment was replaced by RPMI 1640, and the co-culture was
maintained 24 h prior to the assay. HepG2 cells were seeded at a density
of 105 cells/cm2 and maintained 5 days in supplemented minimal essential
medium (MEM) supplemented with 10% (v/v) of iFBS and 1% (v/v) of
antibiotic-antimycotic solution. Five days prior the assay all the cell culture
media was depleted of antibiotic/antimycotic solution. Cells were negative
for Mycoplasma contamination. The cell morphology was analysed by a
Zeiss Primovert inverted microscope (Oberkochen, Germany). Super-
natants from volunteers (2F, 29 yo) showing extreme microbiota
metabolism responses in the short-term incubations were used for
validating whether CX effectively decreases inflammation even after
exposure to the gut microbiota. Volunteer 6 displayed the most significant
decrease in butyrate after 16 h of incubation and was identified as
“responder” to CX supplementation. Volunteer 8 did not present any
changes in fermentation products and was termed “non-responder”.
Triplicate supernatants from each volunteer were passed through a sterile
0.2 µm filter, diluted five times with DMEM without supplementation, pH
was adjusted to pH 7–7.2 with filter-sterilized NaOH 0.5 M (Carl Roth GmbH
& Co), and placed in the apical compartment of the model. Results from
the simplified inflammation model indicated that there were no significant
differences between control and treatment among donors. Thus, we only
included CX solution dissolved in 70:30 (v/v) PEG:H2O or 70:30 (v/v) PEG:
H2O alone in the enterohepatic model. CX solution at 100mg/mL and a
70:30 (v/v) PEG:H2O were diluted 1:5 with DMEM without supplementation,
and added to the apical compartment, as controls of non-bacterially
modified CX and vehicle. This dilution step was performed to simulate low
solubility and the small aqueous volume in the colon.18 LPS (100 ng/mL)
was added to the basal compartment to simulate systemic inflammation.
Plates were incubated for 16 h at 37 °C, 10% CO2 and 95% humidity. TEER
was evaluated with the Millicell ERS-2 Voltohmmeter at the beginning and
at the end of the assay (Merck-Millipore, Overijse, Belgium). Differences in
TEER among treatments were compared using a repeated measures mixed
model in SAS,70 with the lsmeans adjustment and Bonferroni correction for
multiple comparisons, with significance at P < 0.05.
Evaluating inflammatory response. Concentration of IL-8 and CXCL16
were measured in the simplified inflammation model with the Human IL-8
(CXCL-8) and Human CXCL16 Mini ABTS ELISA Development Tests
(PeproTech, London, UK) and the ABTS ELISA Buffer Kit (PeproTech,
London, UK), following the manufacturer’s instructions. Samples were not
diluted, and determination was performed at 405 nm, with correction for
650 nm (Infinite 200 PRO, Tecan, Männedorf, Switzerland). IL-8 was
additionally determined in the presystemic metabolism model, using
samples from the basal compartment diluted 10 times with PBS (ABTS
ELISA Buffer Kit, PeproTech, London, UK), and measured as indicated
above. Multiple pairwise comparisons were completed in GraphPad
(GraphPad Prism 8, La Jolla, CA, USA) using one-way Anova and Tukey’s
test. Statistical significance was assumed at P < 0.05.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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